In a six-month follow-up study, Dutch cardiologists found that patients who received Abbott Vascular's Xience V everolimus-eluting stent were less likely to die or experience heart attacks or artery blockage than those who received bare-metal stents or first-generation drug-coated stents. Although the findings are "reassuring," large-scale studies on the device are still needed, an interventional cardiologist said.

Full Story:

Related Summaries